Chronic Lymphocytic Leukemia

Bruce G. Raphael, MD, discusses the utility of venetoclax and obinutuzumab in chronic lymphocytic leukemia.

Michael Choi, MD, a medical staff physician and associate clinical professor of medicine at the University of California, San Diego (UCSD) Medical Center, discusses emerging treatments in chronic lymphocytic leukemia (CLL).

Paul M. Barr, MD, Wilmot Cancer Institute, University of Rochester, discusses novel combination strategies in chronic lymphocytic leukemia (CLL).

Paul M. Barr, MD, discusses the findings from a phase 1/2 trial and the evolution toward triplet therapies in chronic lymphocytic leukemia.

John M. Pagel, MD, PhD, chief of the Hematologic Malignancies Program, and director, Hematopoietic Cell Transplantation Program, at Swedish Cancer Institute, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

A doublet combining umbralisib and ublituximab improved progression-free survival in patients with chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses remaining questions regarding the use of BTK inhibitors and CD20-directed monoclonal antibodies in chronic lymphocytic leukemia.

The FDA has approved an expanded indication of ibrutinib for use in combination with rituximab for the frontline treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma.

Anthony R. Mato, MD, MSCE, discusses the different research efforts that are being made with immunotherapy in chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses the rationale for combining BTK inhibitors with CD20-directed monoclonal antibodies in CLL, sequencing challenges, and remaining questions in the chronic lymphocytic leukemia.

Jennifer Woyach, MD, discusses the utility of time-limited therapies in chronic lymphocytic leukemia.

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial, which evaluated the efficacy of fixed-duration treatment with venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses questions regarding combination therapies in chronic lymphocytic leukemia.

The addition of acalabrutinib (Calquence) to venetoclax (Venclexta) and obinutuzumab (Gazyva) was shown to be highly active in patients with newly diagnosed chronic lymphocytic leukemia, eliciting deep and durable responses.

Alexey V. Danilov, MD, PhD, discusses the potential for combining venetoclax with novel BTK inhibitors in chronic lymphocytic leukemia.

Bruce G. Raphael, MD, discusses the risk of tumor lysis syndrome in chronic lymphocytic leukemia.

Michael Choi, MD, discusses the utility of duvelisib in chronic lymphocytic leukemia.

Michael Choi, MD, discusses how up-front treatment decisions impact what options can be given in the relapsed/refractory setting for patients with chronic lymphocytic leukemia.

Farrukh Awan, MD, discusses novel approaches under investigation in relapsed/refractory chronic lymphocytic leukemia.

Brad S. Kahl, MD, discusses the use of BTK inhibitors, which have revolutionized the treatment paradigm in chronic lymphocytic leukemia.

Investigators are evaluating whether the addition of venetoclax to a standard doublet regimen in chronic lymphocytic leukemia can induce responses deep enough to allow patients to not only suspend long-term treatment but also avoid associated toxicity.

Matthew S. Davids, MD, MMSc, discusses data that were presented with novel combinations in chronic lymphocytic leukemia at the 2019 ASH Annual Meeting and the importance of conducting cost-effective analyses.

The European Commission has approved a fixed-dose combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

Bruce G. Raphael, MD, a clinical professor in the Department of Medicine at NYU Langone Health, discusses the phase II CLARITY trial in chronic lymphocytic leukemia (CLL).

Jennifer Woyach, MD, discusses current challenges in chronic lymphocytic leukemia treatment.